Clinical Trial

Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients

Study acronym: INSTIGO
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The INSTIGO study aims to assess a plasma protein profile at different stages of patient follow-up as a predictive factor of metastatic recurrence in triple negative breast cancer. It also aims to look at other potential biomarkers of metastatic relapse such as Tumor-infiltrating Lymphocytes, circulating tumor DNA, figurative elements in blood, or a tumor RNA signature.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2020-06-17; most recent amendment 2025-11-27.
Status change: Recruiting → Active, Not Recruiting 2025-11-27
Status change: Not Yet Recruiting → Recruiting 2020-11-17
Trial Details
NCT Number NCT04438681
Lead Sponsor Centre Jean Perrin
Conditions Triple Negative Breast Cancer
Enrollment 90 participants
Start Date 2020-11-27
Primary Completion 2026-11-09 (estimated)
Study Completion 2029-11-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-04